JP2009539412A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009539412A5 JP2009539412A5 JP2009515614A JP2009515614A JP2009539412A5 JP 2009539412 A5 JP2009539412 A5 JP 2009539412A5 JP 2009515614 A JP2009515614 A JP 2009515614A JP 2009515614 A JP2009515614 A JP 2009515614A JP 2009539412 A5 JP2009539412 A5 JP 2009539412A5
- Authority
- JP
- Japan
- Prior art keywords
- ecd
- chimeric polypeptide
- seq
- receptor
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001184 polypeptide Polymers 0.000 claims 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims 29
- 239000003446 ligand Substances 0.000 claims 9
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 8
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 8
- 102000001301 EGF receptor Human genes 0.000 claims 8
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 claims 6
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 claims 6
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 claims 6
- 238000006471 dimerization reaction Methods 0.000 claims 6
- 102000005962 receptors Human genes 0.000 claims 6
- 108020003175 receptors Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 4
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 4
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000000710 homodimer Substances 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims 2
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims 2
- 230000002491 angiogenic effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000000833 heterodimer Substances 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 claims 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000001447 compensatory effect Effects 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 229920002521 macromolecule Polymers 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004850 protein–protein interaction Effects 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81326006P | 2006-06-12 | 2006-06-12 | |
| US84854206P | 2006-09-29 | 2006-09-29 | |
| US87894107P | 2007-01-05 | 2007-01-05 | |
| PCT/US2007/071041 WO2007146959A2 (en) | 2006-06-12 | 2007-06-12 | Pan-cell surface receptor- specific therapeutics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009539412A JP2009539412A (ja) | 2009-11-19 |
| JP2009539412A5 true JP2009539412A5 (enExample) | 2010-07-01 |
Family
ID=38832799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009515614A Withdrawn JP2009539412A (ja) | 2006-06-12 | 2007-06-12 | 汎細胞表面レセプター特異的な治療薬 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100055093A1 (enExample) |
| EP (1) | EP2044115A2 (enExample) |
| JP (1) | JP2009539412A (enExample) |
| KR (1) | KR20090031897A (enExample) |
| AU (1) | AU2007257683A1 (enExample) |
| BR (1) | BRPI0713272A2 (enExample) |
| CA (1) | CA2655205A1 (enExample) |
| IL (1) | IL195909A0 (enExample) |
| NZ (1) | NZ574093A (enExample) |
| SG (1) | SG172692A1 (enExample) |
| WO (1) | WO2007146959A2 (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008312580A1 (en) * | 2007-10-16 | 2009-04-23 | Symphogen A/S | Compositions comprising optimized Her1 and Her3 multimers and methods of use thereof |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| JP2010006705A (ja) * | 2008-06-13 | 2010-01-14 | Atlas Antibodies Ab | Ｈｅｒ２サブセット |
| US9198952B2 (en) | 2008-09-22 | 2015-12-01 | The Brigham And Women's Hospital, Inc. | Compositions of and methods of using ligand dimers |
| WO2010040029A1 (en) * | 2008-10-02 | 2010-04-08 | Celtaxsys, Inc. | Methods of modulating the negative chemotaxis of immune cells |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| RU2012105766A (ru) * | 2009-07-28 | 2013-09-10 | Лигацепт, Лимитед Лиабилити Компани | МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ ШИРОКИЙ СПЕКТР ЛИГАНДОВ ErbB И СПОСОБЫ ИХ ПРИГОТОВЛЕНИЯ И ИСПОЛЬЗОВАНИЯ |
| ES2691717T3 (es) | 2009-10-30 | 2018-11-28 | Novartis Ag | Bibliotecas universales del dominio de unión del lado inferior de tipo iii de la fibronectina de tipo III |
| WO2011060242A2 (en) | 2009-11-13 | 2011-05-19 | Talecris Biotherapeutics, Inc. | Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto |
| US9556249B2 (en) | 2010-02-18 | 2017-01-31 | Genentech, Inc. | Neuregulin antagonists and use thereof in treating cancer |
| WO2011119836A1 (en) | 2010-03-24 | 2011-09-29 | Massachusetts Institute Of Technology | Methods and compositions for cardioprotection and cardioregeneration |
| CN107903321A (zh) | 2010-07-30 | 2018-04-13 | 诺华有限公司 | 纤连蛋白摇篮分子和其库 |
| AU2011290672B2 (en) | 2010-08-20 | 2015-07-09 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (HER3) |
| EP2625196B1 (en) * | 2010-10-05 | 2016-03-23 | Kemijski Institut | Fusion polypeptides comprising tir and dimerization domain for modulation of tlr/innate immunity signaling |
| WO2012103114A2 (en) * | 2011-01-24 | 2012-08-02 | Jason Hill | Therapeutic chimeric ligand binding proteins and methods for their use |
| MX342034B (es) | 2011-02-28 | 2016-09-12 | Hoffmann La Roche | Proteinas monovalentes que se unen a antigenos. |
| AR085404A1 (es) | 2011-02-28 | 2013-09-25 | Hoffmann La Roche | Proteinas de union a antigeno |
| CN102219860B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
| CN102219859B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | 拮抗血管新生诱导因子的融合蛋白及其用途 |
| WO2012162418A1 (en) * | 2011-05-23 | 2012-11-29 | The University Of North Carolina At Chapel Hill | Methods and compositions for heterodimeric targeting ligands |
| KR101397088B1 (ko) | 2011-06-10 | 2014-05-19 | 강원대학교산학협력단 | 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물 |
| WO2012169822A2 (ko) * | 2011-06-10 | 2012-12-13 | 강원대학교산학협력단 | 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물 |
| WO2013003647A2 (en) | 2011-06-28 | 2013-01-03 | Sea Lane Biotechnologies, Llc | Multispecific stacked variable domain binding proteins |
| JP2013040148A (ja) * | 2011-08-19 | 2013-02-28 | Asahi Kasei Corp | シアリルオリゴ糖ペプチド固定化ビーズ |
| ES2670651T3 (es) * | 2011-10-04 | 2018-05-31 | Expression Pathology, Inc. | Ensayo de SRM/MRM para determinar la proteína ERBB-4 del receptor de tirosina-proteína quinasa (HER4) |
| JP2015504038A (ja) | 2011-10-31 | 2015-02-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 低減した免疫原性を有するフィブロネクチン結合ドメイン |
| CN104105709A (zh) * | 2011-12-05 | 2014-10-15 | 诺华股份有限公司 | 抗her3的结构域ii的表皮生长因子受体3(her3)抗体 |
| EP3590538A1 (en) | 2011-12-05 | 2020-01-08 | Novartis AG | Antibodies for epidermal growth factor receptor 3 (her3) |
| WO2013110030A2 (en) | 2012-01-19 | 2013-07-25 | Duke University | Vaccines against antigens involved in therapy resistance and methods of using same |
| JP6224077B2 (ja) | 2012-04-17 | 2017-11-01 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 改変された核酸を用いてポリペプチドを発現させるための方法 |
| MX2014014162A (es) | 2012-05-24 | 2015-02-04 | Hoffmann La Roche | Anticuerpos multiespecificos. |
| EP2727941A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
| EP2914629A1 (en) | 2012-11-05 | 2015-09-09 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
| EP2727943A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Trispecific antibodies against human EGFR, HER2 and HER3 |
| EP2727942A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Bispecific antibodies against human EGFR, HER2, and HER3 |
| AR093778A1 (es) | 2012-11-08 | 2015-06-24 | Hoffmann La Roche | PROTEINAS LIGANTES DE ANTIGENO ANTI-HER3/HER4 DE UNION A LA HORQUILLA b DE HER3 Y A LA HORQUILLA b DE HER4 |
| MA38165A1 (fr) | 2012-11-08 | 2018-07-31 | Hoffmann La Roche | Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3 |
| EP3711484A1 (en) * | 2013-07-05 | 2020-09-23 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Soluble cd33 for treating myelodysplastic syndromes (mds) |
| BR112016006929A2 (pt) | 2013-10-11 | 2017-09-19 | Hoffmann La Roche | Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo |
| JPWO2015099197A1 (ja) * | 2013-12-25 | 2017-03-23 | 国立大学法人佐賀大学 | 肺癌の検査方法 |
| US20160331853A1 (en) * | 2014-01-21 | 2016-11-17 | The Trustees Of Columbia University In The City Of New York | Compositions for radiotherapy and uses thereof |
| MX2016014416A (es) | 2014-05-14 | 2017-02-23 | Hoffmann La Roche | Anticuerpos anti-her3 que se unen a la horquilla beta de her3. |
| EP3166646A4 (en) | 2014-07-07 | 2018-03-07 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| CA2954279C (en) | 2014-07-07 | 2023-11-14 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| WO2016011343A1 (en) * | 2014-07-17 | 2016-01-21 | The Trustees Of The University Of Pennsylvania | Her3 peptides and dendritic cell vaccines |
| WO2017003908A1 (en) | 2015-06-30 | 2017-01-05 | The Trustees Of Columbia University In The City Of New York | Talc-bound compositions and uses thereof |
| US11253580B2 (en) | 2016-01-07 | 2022-02-22 | Duke University | Cancer vaccines and methods of delivery |
| WO2018022929A1 (en) * | 2016-07-27 | 2018-02-01 | The Trustees Of Columbia University In The City Of New York | Gel-bound compositions for radiotherapy and uses thereof |
| US11224665B2 (en) | 2016-10-05 | 2022-01-18 | Duke University | Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same |
| US10487143B2 (en) | 2016-10-05 | 2019-11-26 | Duke University | Vaccines against HER3 antigens and methods of using the same |
| EP3568474A1 (en) | 2017-01-10 | 2019-11-20 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
| US11617797B2 (en) | 2017-04-28 | 2023-04-04 | David T. Tran | Multi-targeted multi-valent ligand drug particles for the treatment and prevention of diseases and conditions |
| CA3065930A1 (en) | 2017-06-07 | 2018-12-13 | Intrexon Corporation | Expression of novel cell tags |
| CN111406071B (zh) * | 2017-11-16 | 2024-01-16 | 成都硕德药业有限公司 | Pas化的vegfr/pdgfr融合蛋白及其在治疗中的用途 |
| US11548931B2 (en) | 2017-11-16 | 2023-01-10 | Xl-Protein Gmbh | PASylated VEGFR/PDGFR fusion proteins and their use in therapy |
| US20210346484A1 (en) * | 2017-12-11 | 2021-11-11 | Medizinische Universitaet Wien | Method of producing a vaccine composition and uses thereof |
| AR121035A1 (es) * | 2019-04-01 | 2022-04-13 | Lilly Co Eli | Compuestos de neuregulina-4 y métodos de uso |
| JP2022540245A (ja) * | 2019-07-11 | 2022-09-14 | ザ クリーヴランド クリニック ファウンデーション | モデルに基づくステントの設計及び配置のためのシステム及び方法 |
| US20210315870A1 (en) * | 2020-04-10 | 2021-10-14 | Postsurgical Therapeutics, Inc. | Combinatorial targeted therapy methods |
| US12268692B2 (en) | 2020-04-10 | 2025-04-08 | Postsurgical Therapeutics, Inc. | Combinatorial targeted therapy methods |
| CA3193273A1 (en) | 2020-08-27 | 2022-03-03 | Enosi Therapeutics Corporation | Methods and compositions to treat autoimmune diseases and cancer |
| WO2023168426A1 (en) | 2022-03-03 | 2023-09-07 | Enosi Therapeutics Corporation | Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof |
| WO2024186690A2 (en) | 2023-03-03 | 2024-09-12 | Enosi Therapeutics Corporation | Oligo-trap fusion proteins (ofps) and uses thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3630200A (en) * | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
| US3847770A (en) * | 1972-04-10 | 1974-11-12 | Continental Can Co | Photopolymerizable compositions prepared from beta hydroxy esters and polyitaconates |
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| EP0171407B1 (en) * | 1984-01-30 | 1993-11-18 | Imperial Cancer Research Technology Limited | Improvements relating to growth factors |
| US4931373A (en) * | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
| US4769027A (en) * | 1984-08-15 | 1988-09-06 | Burroughs Wellcome Co. | Delivery system |
| US4751180A (en) * | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) * | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4687610A (en) * | 1986-04-30 | 1987-08-18 | E. I. Du Pont De Neumours And Company | Low crystallinity polyester yarn produced at ultra high spinning speeds |
| US5401638A (en) * | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5723286A (en) * | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US6136310A (en) * | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5635177A (en) * | 1992-01-22 | 1997-06-03 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
| US5792771A (en) * | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
| US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5354566A (en) * | 1993-06-02 | 1994-10-11 | Kraft General Foods, Inc. | Preparation of yeast-leavened dough crusts |
| US5886026A (en) * | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US5457035A (en) * | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
| IT1270594B (it) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5639757A (en) * | 1995-05-23 | 1997-06-17 | Pfizer Inc. | 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors |
| CA2258721C (en) * | 1996-07-12 | 2014-09-09 | Genentech, Inc. | Chimeric heteromultimer adhesins |
| US7173005B2 (en) * | 1998-09-02 | 2007-02-06 | Antyra Inc. | Insulin and IGF-1 receptor agonists and antagonists |
| US7396810B1 (en) * | 2000-08-14 | 2008-07-08 | Oregon Health Sciences University | Compositions and methods for treating cancer by modulating HER-2 and EGF receptors |
| US7393823B1 (en) * | 1999-01-20 | 2008-07-01 | Oregon Health And Science University | HER-2 binding antagonists |
| US8188231B2 (en) * | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| AU2004265226A1 (en) * | 2003-05-16 | 2005-02-24 | Receptor Biologix, Inc. | Intron fusion proteins, and methods of identifying and using same |
| WO2005033133A2 (en) * | 2003-10-03 | 2005-04-14 | Compugen Ltd. | Polynucleotides encoding erbb-2 polypeptides and kits and methods using same |
| WO2006119510A2 (en) * | 2005-05-04 | 2006-11-09 | Receptor Biologix, Inc. | Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same |
-
2007
- 2007-06-12 JP JP2009515614A patent/JP2009539412A/ja not_active Withdrawn
- 2007-06-12 EP EP07784419A patent/EP2044115A2/en not_active Withdrawn
- 2007-06-12 WO PCT/US2007/071041 patent/WO2007146959A2/en not_active Ceased
- 2007-06-12 US US12/304,467 patent/US20100055093A1/en not_active Abandoned
- 2007-06-12 BR BRPI0713272A patent/BRPI0713272A2/pt not_active IP Right Cessation
- 2007-06-12 SG SG2011041944A patent/SG172692A1/en unknown
- 2007-06-12 AU AU2007257683A patent/AU2007257683A1/en not_active Abandoned
- 2007-06-12 CA CA002655205A patent/CA2655205A1/en not_active Abandoned
- 2007-06-12 NZ NZ574093A patent/NZ574093A/en not_active IP Right Cessation
- 2007-06-12 KR KR1020097000615A patent/KR20090031897A/ko not_active Withdrawn
-
2008
- 2008-12-11 IL IL195909A patent/IL195909A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009539412A5 (enExample) | ||
| CN115057936B (zh) | 异源二聚体多特异性抗体形式 | |
| JP7231641B2 (ja) | 天然抗体様構造を有し、ヘテロ二量体形態の抗ｐｄ－ｌ１／抗ｃｄ４７二重特異性抗体、ならびにその製造方法 | |
| JP7850417B2 (ja) | 新規インターロイキン－２バリアントおよびその二官能性融合分子 | |
| KR102935714B1 (ko) | 수의과 용도를 위한 IgG Fc 변이체 | |
| KR102247704B1 (ko) | 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법 | |
| CN110520445B (zh) | 抗pd-l1/抗pd-1天然抗体结构样异源二聚体形式双特异抗体及其制备 | |
| CN110719918B (zh) | 靶向至少cd3和hsa的异源二聚体多特异性抗体形式 | |
| CN105658235A (zh) | 能够结合gpA33和CD3的双特异性单价双抗体及其用途 | |
| US11753471B2 (en) | Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing same | |
| JP2017527272A5 (enExample) | ||
| SI2802606T1 (en) | Improves the transfer of healing molecules through the hematoencephalic barrier | |
| CN103857700A (zh) | 串联fc双特异性抗体 | |
| IL270897B1 (en) | Immunoglobulin regions that allow heterodimerization | |
| JP2024507693A (ja) | 二重特異性抗体 | |
| KR102776403B1 (ko) | Cd80 단백질 돌연변이체 및 그 응용 | |
| RU2009126545A (ru) | МУЛЬТИМЕРНЫЕ ПОЛИПЕПТИДЫ Fc-РЕЦЕПТОРА, ВКЛЮЧАЮЩИЕ МОДИФИЦИРОВАННЫЙ Fc-ДОМЕН | |
| CN115702169A (zh) | 包含促红细胞生成素多肽的融合蛋白 | |
| CN115066275A (zh) | 包含修饰的ehd2结构域的结合模块 | |
| US20260049118A1 (en) | Single-chain chimeric polypeptides and uses thereof | |
| US20240018201A1 (en) | Methods for purification of multi-specific antibodies | |
| RU2025130619A (ru) | Биспецифические агонистические антитела к рецептору i типа, подобному рецептору активина а (alk1) | |
| EA043006B1 (ru) | Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения | |
| RU2021120860A (ru) | Мультиспецифические связывающие белки на основе псевдо-fab | |
| EA048453B1 (ru) | ГЕТЕРОДИМЕРИЗУЮЩИЕСЯ ДОМЕНЫ Ig |